SCOPUS 정보 검색 플랫폼

Heart

Volumn 95, Issue 18, 2009, Pages 1471-1472

Disease-modifying anti-rheumatic drugs: Do they reduce cardiac complications of RA?

(2) Hamdulay, Shahir S a Mason, Justin C a

a HAMMERSMITH HOSPITAL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORTICOSTEROID THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS;

EID: 69449091439 PISSN: 13556037 EISSN: 1468201X Source Type: Journal
DOI: 10.1136/hrt.2009.171561 Document Type: Editorial

Times cited : (7)

References (17)

1
- 0033598672
- A tale of two diseases: Atherosclerosis and rheumatoid arthritis
- Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-2126
- (1999) Circulation , vol.100 , pp. 2124-2126
- Pasceri, V.¹ Yeh, E.T.²

2
- 0346365086
- Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis
- Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-2963
- (2003) Circulation , vol.108 , pp. 2957-2963
- Sattar, N.¹ McCarey, D.W.² Capell, H.³

3
- 0034761724
- Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus
- DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I
- Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-2337 (Pubitemid 32977500)
- (2001) Arthritis and Rheumatism , vol.44 , Issue.10 , pp. 2331-2337
- Esdaile, J.M.¹ Abrahamowicz, M.² Grodzicky, T.³ Li, Y.⁴ Panaritis, C.⁵ Berger, R.D.⁶ Ce, R.⁷ Grover, S.A.⁸ Fortin, P.R.⁹ Clarke, A.E.¹⁰ Senecal, J.-L.¹¹

4
- 52949103244
- Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
- Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008;121(suppl 1):S3-S8.
- (2008) Am J Med , vol.121 , Issue.SUPPL. 1
- Salmon, J.E.¹ Roman, M.J.²

5
- 0037029418
- Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study
- DOI 10.1016/S0140-6736(02)08213-2
- Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177 (Pubitemid 34304256)
- (2002) Lancet , vol.359 , Issue.9313 , pp. 1173-1177
- Choi, H.K.¹ Hernan, M.A.² Seeger, J.D.³ Robins, J.M.⁴ Wolfe, F.⁵

6
- 34247564814
- Diseasemodifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study
- Van HV, Nurmohamed MT, Twisk JW, et al. Diseasemodifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
- (2006) Arthritis Res Ther , vol.8
- Van, H.V.¹ Nurmohamed, M.T.² Twisk, J.W.³

7
- 10444286732
- Effect of glucocorticoids on the arteries in rheumatoid arthritis
- DOI 10.1002/art.20661
- Del Rincón I, O'Leary DH, Haas RW, et al. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50:3813-3822 (Pubitemid 39643928)
- (2004) Arthritis and Rheumatism , vol.50 , Issue.12 , pp. 3813-3822
- Del Rincon, I.¹ O'Leary, D.H.² Haas, R.W.³ Escalante, A.⁴

8
- 35348901566
- Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus
- DOI 10.1002/art.22924
- Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-3419 (Pubitemid 47585436)
- (2007) Arthritis and Rheumatism , vol.56 , Issue.10 , pp. 3412-3419
- Roman, M.J.¹ Crow, M.K.² Lockshin, M.D.³ Devereux, R.B.⁴ Paget, S.A.⁵ Sammaritano, L.⁶ Levine, D.M.⁷ Davis, A.⁸ Salmon, J.E.⁹

9
- 47249153519
- Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics
- DOI 10.1111/j.1600-065X.2008.00626.x
- Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19. (Pubitemid 351986171)
- (2008) Immunological Reviews , vol.223 , Issue.1 , pp. 7-19
- Feldmann, M.¹ Maini, S.R.N.²

10
- 0037159293
- Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis
- DOI 10.1161/01.CIR.0000037521.71373.44
- Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-2187 (Pubitemid 35222210)
- (2002) Circulation , vol.106 , Issue.17 , pp. 2184-2187
- Hurlimann, D.¹ Forster, A.² Noll, G.³ Enseleit, F.⁴ Chenevard, R.⁵ Distler, O.⁶ Bechir, M.⁷ Spieker, L.E.⁸ Neidhart, M.⁹ Michel, B.A.¹⁰ Gay, R.E.¹¹ Luscher, T.F.¹² Gay, S.¹³ Ruschitzka, F.¹⁴

11
- 33748644710
- Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by antitumor necrosis factor-alpha therapy
- Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by antitumor necrosis factor-alpha therapy. Circulation 2006;114:1185-1192
- (2006) Circulation , vol.114 , pp. 1185-1192
- Maki-Petaja, K.M.¹ Hall, F.C.² Booth, A.D.³

12
- 32544436599
- Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis
- DOI 10.1002/art.21707
- Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006;55:150-153 (Pubitemid 43235141)
- (2006) Arthritis Care and Research , vol.55 , Issue.1 , pp. 150-153
- Gonzalez-Juanatey, C.¹ Llorca, J.² Garcia-Porrua, C.³ Martin, J.⁴ Gonzalez-Gay, M.A.⁵

13
- 34848898513
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register
- DOI 10.1002/art.22809
- Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-2912 (Pubitemid 47502736)
- (2007) Arthritis and Rheumatism , vol.56 , Issue.9 , pp. 2905-2912
- Dixon, W.G.¹ Watson, K.D.² Lunt, M.³ Hyrich, K.L.⁴ Silman, A.J.⁵ Symmons, D.P.M.⁶ Maiden, N.⁷ Price, T.⁸ Hopkinson, N.⁹ O'Reilly, S.¹⁰ Hordon, L.¹¹ Griffiths, I.¹² Porter, D.¹³ Capell, H.¹⁴ Hassell, A.¹⁵ Benitha, R.¹⁶ Choy, E.¹⁷ Walsh, D.¹⁸ Emery, P.¹⁹ Knight, S.²⁰ more..

14
- 17444394445
- Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
- Bresnihan B, varo-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204
- (1998) Arthritis Rheum , vol.41 , pp. 2196-2204
- Bresnihan, B.¹ Varo-Gracia, J.M.² Cobby, M.³

15
- 2342551979
- Combination Therapy with Etanercept and Anakinra in the Treatment of Patients with Rheumatoid Arthritis Who Have Been Treated Unsuccessfully with Methotrexate
- DOI 10.1002/art.20221
- Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419 (Pubitemid 38608062)
- (2004) Arthritis and Rheumatism , vol.50 , Issue.5 , pp. 1412-1419
- Genovese, M.C.¹ Cohen, S.² Moreland, L.³ Lium, D.⁴ Robbins, S.⁵ Newmark, R.⁶ Bekker, P.⁷

16
- 47649086507
- Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis
- Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008;117:2662-2669
- (2008) Circulation , vol.117 , pp. 2662-2669
- Ikonomidis, I.¹ Lekakis, J.P.² Nikolaou, M.³

17
- 69449087866
- Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis
- Ikonomidis I, Tzortzis S, Lekakis J, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 2009;95:1502-1507
- (2009) Heart , vol.95 , pp. 1502-1507
- Ikonomidis, I.¹ Tzortzis, S.² Lekakis, J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.